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Abstract
Introduction: Extramedullary plasmacytoma is a rare plasma cell neoplasm. Plasmacytomas are most commonly
found in the head and neck region, but can occur in many other locations. They rarely occur in the testis, and are
commonly associated with concurrent multiple myeloma at the time of diagnosis. Isolated plasmacytoma of the
testis is exceedingly rare, with few cases reported in the literature.
Case presentation: A 72-year-old Caucasian man presented with a painless testicular mass treated by
orchiectomy. The mass was determined to be plasmacytoma on pathological examination. At the time of
diagnosis, our patient did not have multiple myeloma, and is currently undergoing chemotherapy for treatment of
his disease.
Conclusion: Isolated plasmacytoma of the testicle is a rare cause of testicular mass, and is seldom reported in the
literature. Patients with this disease require careful monitoring because of their high risk of progression to multiple
myeloma. The diagnosis of testicular plasmacytoma can be challenging for primary care doctors and urologic
specialists. This condition should be in the differential diagnosis in elderly men.
Introduction
Patients presenting with extramedullary plasmacytoma
(EMP) often present with signs and symptoms of diffuse
disease. These patients are generally diagnosed with multi-
ple myeloma at the time of presentation. EMP can occur
in many different locations in the body. The most com-
mon anatomic site for the disease is the head and neck
region, particularly of the respiratory or gastrointestinal
tracts. Occasionally, these tumors are located in other
organ systems including lymph nodes, liver, skin and, very
rarely, the testis [1-3]. Cases of isolated testicular plasma-
cytoma are extraordinarily rare, with few cases reported in
the literature to date [4]. These patients have a high rate
of progression to disseminated disease, and they require
close monitoring after appropriate treatment [1,2,5]. We
discuss a case of isolated testicular plasmacytoma in a 72-
year-old patient with ensuing progression to multiple
myeloma.
Case presentation
A 72-year-old Caucasian man presented to clinic com-
plaining of a painless left testicular mass. He had no asso-
ciated bone pain or weight loss. A physical exam revealed
a nontender 3 by 5 cm indurated mass in his left testicle.
A comprehensive metabolic panel and complete blood
count (CBC) revealed a total protein of 8.3, but were
otherwise normal. Tumor markers (a-fetoprotein, lactate
dehydrogenase, b-human chorionic growth hormone)
were negative. On a scrotal ultrasound, the mass appeared
multilobar and heterogeneous, thus raising concern for
malignancy (Figure 1). Our patient underwent an uncom-
plicated left inguinal radical orchiectomy. Pathologic eva-
luation of the testicular mass demonstrated plasmacytoma
(Figure 2). Serum protein electrophoresis (SPEP) showed
an immunoglobulin A (IgA) level of 2631 mg/dL indicative
of monoclonal gammopathy of undetermined significance
(MGUS). A skeletal survey was negative for coexisting
lesions. A bone marrow biopsy was negative for clonal
plasma cells. Our patient continued follow-up with medi-
cal oncology and subsequently developed metastatic dis-
ease two and a half years later, detected by skeletal survey.
He is currently being treated with the chemotherapeutic
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acid.
Discussion
Plasma cell neoplasms are divided into two different
categories: multiple myeloma and solitary plasmacytoma.
Solitary plasmacytomas are most commonly found in
the bone, however they can also be extramedullar. 90%
of all EMPs are found in the head and neck region, par-
ticularly the upper respiratory and digestive tracts.
Other locations include the gastrointestinal tract, central
nervous system, skin and, rarely, the testis. EMPs
account for only 3% of plasma cell malignancies. The
mean age of diagnosis is 55 to 60 years, with a male to
female ratio of two to one [1-3]. The diagnosis of EP
requires many diagnostic studies including CBC with
differential and smear, complete metabolic panel, SPEP
with immunofixation of immunoglobulins, biopsy of the
lesion, bone aspiration and biopsy, and metastatic bone
survey by positron emission tomography (PET) with
computed tomography (CT) or magnetic resonance ima-
ging (MRI). By definition, patients with EMP cannot
have symptoms of multiple myeloma including anemia,
hypercalcemia, or renal insufficiency. The lesion should
have evidence of clonal plasma cells, and the bone mar-
row biopsy must contain no clonal plasma cells. Some
patients may have small amounts of monoclonal protein,
usually IgA, in the serum or urine. The marrow of some
patients may have up to 10% clonal plasma cells. These
patients are considered to have both EMP and MGUS.
These patients have higher risk of progressing to multi-
ple myeloma [3,6]. The treatment of these tumors is
either radiation therapy or surgical resection. Adjuvant
radiation or chemotherapy does not improve the out-
come. In patients with incomplete resection, local radia-
tion is the best treatment. Less than 10% of patients
develop local recurrence. These patients have high rates
of progression to multiple myeloma, up to 15% [7]. The
overall 10-year survival for patients with EMP is 70%
[3].
Isolated testicular plasmacytoma accounts for only 0.03-
0.1% of all testicular tumors [1,7]. The vast majority of
patients with testicular plasmacytoma either have dissemi-
nated disease at the time of diagnosis, or develop dissemi-
nated disease later in life [1,2,5]. This case is therefore
unusual due to the primary nature of the plasmacytoma
within the testis. The age of diagnosis ranges from 26 to
83 years of age, although the mean age of diagnosis in 55
to 60 years old [4]. The incidence of plasmacytoma also
increases with age [8]. Patients commonly present with a
firm testicular mass, which may or may not be tender.
Patients with disseminated disease may also present with
symptoms of multiple myeloma such as back pain. On
gross examination, the tumors are soft, fleshy, and white
or grey in color [4]. On ultrasound, plasmacytoma of the
testicle can be either homogeneous or heterogeneous, and
typically hypoechoic. Hyperemia on Doppler imaging has
also been observed in these tumors, although hyperemia is
also characteristic of many types of testicular tumors [5,9].
On microscopic examination, the tumor appears as sheets
of atypical plasma cells with varying degrees of differentia-
tion [5]. Plasmacytomas can be mistaken for other types of
tumors, including seminoma, lymphoma and metastatic
melanoma [2,4]. In order to make accurate diagnosis,
immunologic staining for CD 138, CD 79a and monoclo-
nal antibody VS 38 can be used [4]. Additionally, immu-
nostaining will reveal IgG, IgD or IgA light chains; IgA
Figure 1 Ultrasound image of the left testicle. Arrow annotates
abnormal mass lesion within testicular parenchyma.
Figure 2 Hematoxylin and eosin stain of a section of the
tumor removed from the left testicle.
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testicular plasmacytoma is radical orchiectomy. In addi-
tion, these tumors are highly radiosensitive so a combina-
tion of surgery and radiation can be implemented. For
patients with residual disease after surgery, or recurrent or
refractory disease, radiation can be used as well [4]. The
overall prognosis for patients with testicular plasmacytoma
is poor, with high rates of progression to multiple mye-
loma. Because of the high rates of progression, these
patients require close monitoring and long-term surveil-
lance. There are no established guidelines as to which
tests are appropriate for surveying for metastatic disease,
or for the frequency or duration of surveillance. A com-
mon approach includes a combination of periodic history
and physical exam, laboratory tests (urine and serum pro-
tein electrophoresis with immunofixation, CBC, serum
creatinine, serum calcium) and imaging such as PET with
or without CT or MRI at lengthening intervals.
Conclusion
EMP is a rare form of plasma cell neoplasm. This tumor
can present in many locations in the body, the testicle
being one of the rarer sites. When plasmacytomas occur
in the testis, the diagnosis can be difficult. Plasmacytomas
often resemble other more common causes of testicular
mass, and require multiple diagnostic tests for accurate
diagnosis. Plasmacytomas often present concurrently
with multiple myeloma, but can present as an isolated
tumor. Patients with isolated plasmacytoma have high
rates of progression to multiple myeloma later in life. For
this reason, it is important to accurately diagnose plasma-
cytoma and survey these patients appropriately for pro-
gression to disseminated disease. Plasmacytoma of the
testicle is exceedingly rare, but an important disease to
consider in patients presenting with testicular mass, par-
ticularly an elderly patient.
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